174 related articles for article (PubMed ID: 35228506)
21. NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expression.
Montastruc JL; Biron P; Sommet A
Fundam Clin Pharmacol; 2022 Dec; 36(6):1125-1127. PubMed ID: 35502459
[TBL] [Abstract][Full Text] [Related]
22. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
Petrovsky N
Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
[TBL] [Abstract][Full Text] [Related]
23. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Gorman MJ; Patel N; Guebre-Xabier M; Zhu A; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yaun D; Bowman K; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger D; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
bioRxiv; 2021 Feb; ():. PubMed ID: 33564763
[TBL] [Abstract][Full Text] [Related]
24. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
Hildt E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
[TBL] [Abstract][Full Text] [Related]
25. A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax
Kim HY; Cho JY; Yoon HJ; Choi YD; Ahn Y; Jeong MH; Cho JG; Kim KH
J Korean Med Sci; 2022 Aug; 37(34):e265. PubMed ID: 36038960
[TBL] [Abstract][Full Text] [Related]
26. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
Tumban E
Viruses; 2020 Dec; 13(1):. PubMed ID: 33396343
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
28. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
Li Q; Wang J; Tang Y; Lu H
Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
[TBL] [Abstract][Full Text] [Related]
29. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Alter G; Gorman M; Patel N; Guebre-Xabier M; Zhu A; Atyeo C; Pullen K; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman K; Zhou B; Maciejewski S; McGrath M; Logue J; Frieman M; Montefiori D; Schendel S; Saphire EO; Lauffenburger D; Greene A; Portnoff A; Massare M; Ellingsworth L; Glenn G; Smith G; Mann C; Amanat F; Krammer F
Res Sq; 2021 Feb; ():. PubMed ID: 33619473
[TBL] [Abstract][Full Text] [Related]
30. Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Fries L; Formica N; Mallory RM; Zhou H; Plested JS; Kalkeri R; Moldovan I; Patel N; Albert G; Robinson M; Cho I; Chau G; Dubovsky F; Glenn GM;
J Infect Dis; 2023 Sep; 228(6):734-741. PubMed ID: 37210741
[TBL] [Abstract][Full Text] [Related]
31. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
32. In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.
Granwehr BP
Ann Intern Med; 2022 May; 175(5):JC52. PubMed ID: 35500261
[TBL] [Abstract][Full Text] [Related]
33. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
34. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
35. Novavax offers first evidence that COVID vaccines protect people against variants.
Callaway E; Mallapaty S
Nature; 2021 Feb; 590(7844):17. PubMed ID: 33510489
[No Abstract] [Full Text] [Related]
36. The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.
Sacks HS
Ann Intern Med; 2021 Nov; 174(11):JC124. PubMed ID: 34724399
[TBL] [Abstract][Full Text] [Related]
37. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
Kim HK; Park SK; Choe SA; Gwak ES; Cowling BJ; Kim YM; Lee KH; Lee SW; Kwon GY; Jang EJ; Kim RK; Choe YJ; Kwon D
Vaccine; 2024 Mar; 42(7):1440-1444. PubMed ID: 38365479
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
39. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
Front Immunol; 2021; 12():719077. PubMed ID: 34394127
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
